anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a recombinant protein, an expression method, a purification method and application thereof. The recombinant protein is F protein of RSV (respiratory syncytial virus), namely RSV-F, the nucleotide sequence of the RSV-F is shown in a sequence table SEQ ID No.1, and the amino acid sequence of the RSV-F protein is shown in a sequence table SEQ ID No. 2. The expression method of the recombinant protein comprises the following steps: 1) amplification of the RSV-F coding fragment; 2) constructing a subclone plasmid containing F protein according to the amplified RSV-F coding segment; 3) constructing a eukaryotic expression plasmid of RSV-F according to the subcloning plasmid; 4) transfecting the eukaryotic expression plasmid of the RSV-F into HEK293E cells, and culturing in a culture medium. And purifying the recombinant protein by an anion exchange column, a cation exchange column and a gel filtration chromatographic column. The purified RSV-F recombinant protein has immunogenicity, and can be used for the development of RSV subunit vaccine or immunodiagnosis of RSV infection.
Pediatric Population: The incidence of serious rash associated with hospitalization and discontinuation of LAMICTAL in a prospectively followed cohort of pediatric patients (2 to 16 years of age) with epilepsy receiving adjunctive therapy was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3 expert dermatologists, there was considerable disagreement as to their proper classification. To illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome; another assigned 7 of the 14 to this diagnosis. There was 1 rash-related death in this 1,983-patient cohort. Additionally, there have been rare cases of toxic epidermal necrolysis with and without permanent sequelae and/or death in US and foreign postmarketing experience.

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of 952) patients not taking valproate. 

Adult Population: Serious rash associated with hospitalization and discontinuation of LAMICTAL occurred in 0.3% (11 of 3,348) of adult patients who received LAMICTAL in premarketing clinical trials of epilepsy. In the bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive therapy. No fatalities occurred among these individuals. However, in worldwide postmarketing experience, rare cases of rash-related death have been reported, but their numbers are too few to permit a precise estimate of the rate.

Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and those associated with multiorgan hypersensitivity [see Warnings and Precautions (5.2)].

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered LAMICTAL with valproate in epilepsy clinical trials, 6 (1%) were hospitalized in association with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers administered LAMICTAL in the absence of valproate were hospitalized.

Patients With History of Allergy or Rash to Other Antiepileptic Drugs: The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation of LAMICTAL is exceeded and in patients with a history of allergy or rash to other AEDs.
OBJECTIVES: I. Determine the maximum tolerated dose and recommended phase II dose of docetaxel in combination with epirubicin and filgrastim (G-CSF) as first-line therapy in women with metastatic breast cancer (phase II closed as of 03/27/2000). II. Determine the pharmacokinetic profile of docetaxel and epirubicin in these patients. III. Evaluate the toxicity of this regimen given at the recommended phase II dose. IV. Determine the response rate and duration of response in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of epirubicin and docetaxel. Patients receive epirubicin IV over 15 minutes followed by docetaxel IV over 60 minutes on day 1. Patients also receive filgrastim (G-CSF) subcutaneously on days 4-13. Treatment continues every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of epirubicin and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose in which at least 2 of 6 patients experience dose-limiting toxicity. Additional patients will be accrued to receive treatment at the recommended phase II dose (phase II closed as of 03/27/2000). Patients are followed at 1 month and then every 3 months for survival.

PROJECTED ACCRUAL: Approximately 15-20 patients will be accrued within 4-5 months for the phase I portion of the study. A total of 15-30 patients will be accrued within 7-8 months for the phase II portion of the study (closed as of 03/27/2000).
PURPOSE: To obtain the subject composition capable of administering a pharmacodynamically effective ingredient at a constant rate for a long period in release behavior of zero order without causing the initial burst of the pharmacodynamically effective ingredient by dissolving or uniformly dispersing finasteride in two or more copolymers having specific copolymerization ratios. CONSTITUTION: This composition is obtained by dissolving or uniformly dispersing (A) finasteride in (B) lactic acid-glycolic acid copolymers having two or more different copolymerization ratios, preferably comprising (i) at least one copolymer having (1:9) to (2:8) copolymerization ratio (L-lactic acid/glycolic acid) of the lactic acid to glycolic acid and (ii) at least one copolymer having (4:6) to (9:1) copolymerization ratio (L-lactic acid/glycolic acid). Furthermore, the compositional ratio of the ingredients (i) to (ii) is preferably (1:100) to (100:1) and the number-average molecular weight of the ingredient (B) is preferably 1500-5000. The compositional ratio of the ingredients is preferably 0.1-100 pts.wt. ingredient (B) based on 1 pt.wt. ingredient (A).
New medicinal preparations with cytostatic activity contain cpds. of formula (I); (where R1 and R2 are each H or opt. substd. 1-12C hydrocarbyl or R1 and R2 together form a ring system or a residue (R3)(R4)C: in which R3 and R4 are H or opt. substd. 1-12C hydrocarbyl or together form a ring system; and glycidyl is a residue of formula (Ia); in which R3 is H or 1-4C alkyl; or one of the glycidyl residues may be replaced by a second ring of formula (I) linked via a hydrocarbon gp.). (I) have cytostatic activity and are suitable for use in the therapy of malignant neoplasms. (I) may be prepd. by reaction of corresp. 1,3-unsubstd. hydantoins with epihalohydrin in the presence of alkali, or by epoxidation of corresp. N-acyl-substd. hydantoins.
A recruitment assessment videoconference is scheduled at the 1st post-discharge week providing clear instructions on how to perform daily TUG test. The TUG test is to be performed at least twice in the morning and twice afternoon and complimented by other specific training exercises as specified in HSH1. Training instructions and assessment is performed by videoconference to ascertain that both the patient and the caregiver can follow instructions in using the "remote-TUG" smartphone app and safety measures are understood and applied when assisting the patients in exercises. Clear video instructions and multimedia for review will be provided. Interim videoconference will be conducted again after week 2 to ascertain adherence. Non-adherence can be immediately detected by remote data collection from the "remote-TUG" server interface. Non-adherence will trigger phone calls and videoconferences serving as reminders and performing troubleshooting.
Anaphylaxis is a potentially life-threatening entity that requires both immediate recognition and aggressive treatment. Although anaphylaxis is infrequent, comprising only 1% of approximately 1.03 million visits to the ED each year that are related to allergic reactions, it is none the less a generally under-recognized and under-treated disease, that is worthy of study due to the potential for a fatal outcome. Recently, there has been renewed interest in a commonly used and inexpensive drug (heparin) as a novel component of therapy for anaphylactic/anaphylactoid reactions. Heflin eft al. induced anaphylactoid reactions in pigs and compared intravenous unfractionated heparin in one treatment arm to standard therapy (intravenous epinephrine and diphenhydramine) versus placebo. The study revealed that heparin rapidly reversed the shock similar to that of standard emergency treatment. Of course this single study done in pigs will not change practice, but it does warrant further investigation into the role that heparin plays in anaphylaxis in humans.
The invention provides a high cholesterol treating drug, relates to applications of celery seed, oats and the like in drugs or health, and belongs to the field of natural drugs or health products. The high cholesterol treating drug is characterized by comprising 10-20 g of celery seed, 15-20 g of semen cassiae, 20-25 g of oat, 30-40 g of fallopia multiflora(thunb.) harald, and 15-20 g of jellyfish. According to the present invention, celery seeds are dried in the sun, the dried celery seeds are grinded into powder, semen cassiae is dried in the sun, the dried semen cassiae is grinded into powder, oat is dried in the sun, the dried oat is grinded into powder, fallopia multiflora(thunb.) herald is dried in the sun, the dried fallopia multiflora(thunb.) harald is grinded into powder, jellyfish is dried in the sun, the dried jellyfish is grinded into powder, the obtained powders are mixed according to the ratio, and about 25 g of the drug is taken 3-5 times a day; and the high cholesterol treating drug has a high medical value.
The present invention provides a graphical user interface for presentation, exploration and verification of patient information. In various embodiments, a method is provided for browsing mined patient information. The method includes selecting patient information to view, at least some of the patient information being probabilistic, presenting the selected patient information on a screen, the selected patient information including links to related information (Fig. 3). The selected patient information may include elements, factoids, and/or conclusions. The selected patient information may include an element linked to unstructured information. For example, an element linked to a note with highlighted information may be presented (Fig. 4). Additionally, the unstructured information may include medical images and waveform information.
Participants received rituximab 375 milligrams per square meter (mg/m\^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
This is a cross-sectional study performed in the 1st Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. For the purposes of this study, adult (aged ≥18 years) CKD patients (defined based on the KDIGO criteria) fulfilling the inclusion and exclusion criteria were invited to participate. All included patients signed a written informed consent form prior to study enrollment. The study protocol was approved by the Ethics Committee of the School of Medicine, Aristotle University of Thessaloniki and the and the Institutional Review Board of Hippokration Hospital, Thessaloniki, Greece. All procedures and evaluations are performed according to the Declaration of Helsinki 2013 Amendment and directives of the General Data Protection Regulation (GDPR).

Baseline evaluation includes the recording of demographics, anthropometric characteristics, CKD cause, comorbidities, concomitant medications, as well as a detailed physical examination and venous blood sampling for routine laboratory tests. Study participants are advised to refrain from food, caffeine, alcohol, or tobacco for 12 h and receive any standard medication before their morning appointment in the research laboratory to perform the assessments described below. Office BP measurements are performed thrice after 5-10 min of rest, in the sitting position, at the level of the brachial artery, with a validated oscillometric device \[Omron M3 Intellisense (Omron Healthcare, Kyoto, Japan)\] using a cuff of appropriate size, according to current guidelines. Afterwards, evaluation of patient's hydration status will be performed with lung ultrasound \[GE VScan (GE Healthcare, Horten, Norway)\] through quantification of US-B lines. The Mini-Mental State Exam (MMSE) is used for the assessment of cognitive function; sleep quality is evaluated by the Pittsburg Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS), while the severity of nocturia is also recorded. Following that, patients will undergo a 24-hour ambulatory BP monitoring (ABPM) with ABPMpro (SOMNOmedics, Randersacker, Germany) with an appropriately sized cuff. The device will take measurements every 20 minutes between 07:00 and 23:00 (daytime period) and every 30 minutes between 23:00 and 07:00 (nighttime period). Simultaneously, patients will perform a 24-hour urine collection, divided in two distinct periods (daytime and nighttime) with the use of two different containers matching the corresponding ABPM periods.
To assess regulatory effect of Mediterranean diet for occupational noise exposure and hearing loss. Methods: This cross-sectional study included 4757 individuals. Weighted logistic regression model was adopted to explore the association of occupational noise exposure and Mediterranean diet with hearing loss, and regulatory effects of the Mediterranean diet for the relationship of occupational noise exposure and hearing loss. Results: Occupational noise exposure was associated with an increased odds of hearing loss. Under low adherence to the Mediterranean diet, the occupational noise exposure group was related to increased odds of hearing loss. Under high adherence to the Mediterranean diet, no significant difference was observed between occupational noise exposure and hearing loss, and adjusted effect size was reduced accordingly. Conclusion: Mediterranean diet may moderate this relationship of occupational noise exposure and hearing loss to some degree.
Patients undergo surgical resection on day 1. Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.
PURPOSE: Provided is a composition comprising the extract or fraction isolated from Russian mumie for activation of immunity. The composition particularly contains FA1, FA2 or FA3 fractions derived from fulvic acid as the extract of Russian mumie, and thus increases immunity or prevents or treats infectious diseases. CONSTITUTION: The extract or fraction of fulvic acid derived from Russian mumie increases the production of ROS(reactive oxygen species), such as superoxide anion and hydrogen peroxide, and NO(nitric oxide) in the microphage. Further, the extract or fraction increases the propagation of splenocytes. Therefore, the extract or fraction is used for medicines increasing immunity. The composition comprising the extract or fraction for activation of immunity is manufactured by the steps of: pulverizing Russian mumie, followed by stirring at room temperature for 12-48 hours after addition of the alkali solution, and centrifugation to give the crude extract of Russian mumie; adding the strong acid to the crude extract, followed by centrifugation to give fulvic acid(FA) and humic acid(HA) as pH value the supernatant; adding the strong acid to the supernatant to adjust to 6.5-8.0, followed by filtration to give the FA solution; fractioning the FA solution to give FA1 and FA2 fractions by adding ethanol to the FA solution; dyalizing the FA solution , followed by performing DEAE-cellulose column and eluting with 0.3-0.2 mole of the sodium chloride solution to give FA3, FA4 and FA5 fractions; and concentrating the 85% ethanol-fractions, followed by re-precipitation to give LMW1 and LMW2 fractions.
PURPOSE:To obtain the title hybridoma containing little impurities, with high specificity, capable of secreting in high reproducibility anti-Candida antibody having high potency, by fusion of antibody-productive cells with cells capable of in vitro long-term subculture. CONSTITUTION:An animal species including human being is immunized with Candida, and antibody-productive cells (plasma cells and lymphocytes as their precursors) are prepared from host with its antibody titer to the Candida in the serum sufficiently enhanced. Thence, the antibody-productive cells are fused with myeloma cells in the presence of a fusion promotor, and the resultant hybridoma is separated from the parent cells followed by cloning using limiting dilution method or soft agar technique etc., thus establishing the objective hybridoma (e.g. CD-1-CD-9). The resultant hybridoma is incubated in vitro or in vivo to produce anti-Candida antibody. Use of this antibody will enable rapid and highly reliable immobilization of Candida.
Risk Summary

Fentanyl is present in breast milk. One published lactation study reports a relative infant dose of fentanyl of 0.024%. However, there is insufficient information to determine the effects of fentanyl on the breastfed infant and the effects of fentanyl on milk production. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with ACTIQ. 

Clinical Considerations

Monitor infants exposed to ACTIQ through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
Multidrug resistant and virulent MRSA strains have been disseminating worldwide and few alternatives of treatment for diseases caused by this pathogen are available. In this study, 36 isolates from colonization or different clinical specimens from infected patients of the Hospital Rizoleta Tolentino Neves will be analyzed. These results will provide important data for doctors and nurses, such as whether there is any strain dissemination or not in the hospital what could suggest an outbreak. It will be performed molecular typing by pulsed field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). The investigators will evaluate the efficiency of several antimicrobials and the frequency of h-VISA and VISA among the Brazilian MRSA. Besides, the investigators will verify the presence of mutation in genes that are involved in resistance mechanisms of VISA. According to the strains profile present in the hospital, if this is suggested that there is a dissemination of some strain, the health professionals can start a more rigid infection control measures in order to decrease the number of cases of nosocomial infection, decreasing the time of hospitalization of patients and, consequently the cost for the hospital.
The overall purpose of this study is to evaluate the safety and efficacy of co-administration of TXA with HA in reducing swelling, bruising and pain after facial injection. Researchers will do this by comparing HA to HA+TXA in participants undergoing facial filler injections. Participants undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Therefore, researchers have designed this as a half face study. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Researchers will then assess swelling, bruising, pain, and overall satisfaction using participant self-reported surveys, physician surveys, and review of medical records.
The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
Postmastectomy breast reconstruction is becoming increasingly utilized in breast cancer patients to provide surgical restoration of the breast mounds. The breast reconstruction discussions can be highly complex, as there are many different techniques, timing, and complications that are unique to each procedure. However ¼ of women report being dissatisfied with some component of their cancer or reconstructive care. Failure of the physician to provide adequate information about treatment options is the most frequent source of cancer patient dissatisfaction and breast reconstruction patients have expressed a need for further information regarding the complex decision to pursue breast reconstruction. In such scenarios of complex medical decision-making, decision support techniques may be an effective solution to information provision and shared decision-making. As a result, the investigators developed a pre-consultation educational group intervention delivered in a group setting for women considering breast reconstruction, with the aims to fill an existing information-gap, promote high-quality decision-making and enhance decision self-efficacy and other decision measures. This pilot study will be the first step in the evaluation of the educational group intervention and the results will be used to determine the feasibility and inform the optimal design for a definitive randomized controlled trial. This study will first examine the feasibility and acceptability of the intervention through implementation in a pilot, mixed-methods, 1:1 allocation parallel-arm randomized controlled trial.
OBJECTIVES: A seizure action plan (SAP) is a powerful tool that provides actionable information for caregivers during seizures. Guidelines have expressed the need for individualized SAPs. Our quality improvement team aimed to increase implementation of an SAP within a pediatric tertiary center, initially among epilepsy providers and expanded to all neurology providers.
METHODS: Process changes were implemented using Plan-Do-Study-Act cycles and data were evaluated monthly using control charts. The team focused on tracking patients who received SAPs and identified opportunities for improvement, including reminders within the electronic medical record, and standardizing clinic processes. A secondary analysis was performed to trend emergency department (ED) use among our patient population.
RESULTS: The SAP utilization rate among epilepsy providers increased from a baseline of 39% to 78% by December 2019 and reached the goal of 85% by June 2020, with a further increase to 92% by February 2022 and maintained. The SAP utilization rate among general neurology providers increased from 43% in 2018 to 85% by July 2020, and further increased to 93% by February 2022 and maintained. ED visits of established patients with epilepsy decreased from a baseline of 10.2 per 1000 to 7.5 per 1000.
CONCLUSIONS: Quality improvement methodologies increased the utilization of a standardized SAP within neurology outpatient care centers. The SAP is a simplified tool that allows patients and providers to navigate a complex health care system. The utility of an SAP may potentially extend to minimizing unnecessary ED visits.